Abstract 43P
Background
Endometrial cancer (EC) is one of the most frequent gynaecological malignant diseases whose incidence presents an increasing trend. Cancer stem cells (CSC), a subpopulation of undifferentiated tumour cells identified in EC, are the main actors in the resistance mechanisms to conventional therapies. Thus, the main aim of this study is to identify novel molecular targets in endometrial CSC for the future development of innovative targeted therapies for EC.
Methods
Two EC cell lines, ECC-1 and RL95-2, were cultured, and endometrial CSC were obtained through an optimized 5-day sphere formation assay. A proteomic profile of cell lines and endometrial CSC was determined through mass spectrometry-based proteomics. The analysis was performed through the comparison of CSC vs. cell line proteins significantly up-regulated by a 40-fold change and their cellular localization. R package was used for statistical analysis.
Results
The proteomic analysis of ECC-1 samples allowed the identification of 477 up-regulated ECC-1-CSC-specific proteins, 108 ECC-1-specific proteins, and 2306 common proteins. Regarding RL95-2 samples, the analysis identified 76 up-regulated RL95-2-CSC-specific, 994 cell line-specific, and 1420 common proteins. The cellular localization of up-regulated proteins identified from CSC populations was mainly the cytoplasm (25-31%), nucleus (19-23%), and membrane (21-22%). Regarding the functional analysis, the more regulated subcategories were the intracellular ferritin complex, poly(A) RNA binding, (acetyl-CoA carboxylase) kinase activity, (hydroxymethylglutaryl-CoA reductase (NADPH)) kinase activity, and ubiquitinyl hydrolase activity for ECC-1-CSC vs. ECC-1; the proteasome, cytosol, extracellular vesicular exosome, poly(A) RNA binding, glutamate dehydrogenase (NAD+) activity, and glutamate dehydrogenase (NADP+) activity for RL95-2-CSC vs. RL95-2; and poly(A) RNA binding, (acetyl-CoA carboxylase) kinase activity, NADPH kinase activity, and ubiquitinyl hydrolase activity for both.
Conclusions
CSC population-specific proteins were identified, as well as their cellular localization and functional enrichment. This information allows for the future development of endometrial CSC targeted therapies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Univ Coimbra.
Funding
Centre for Innovative Biomedicine and Biotechnology (CIBB) (UIDB/04539/2020, UIDP/04539/2020) is supported by The Fundação para a Ciência e a Tecnologia (FCT), co-funded by COMPETE. Beatriz Serambeque was awarded a PhD Scholarship from FCT and European Social Fund (2020.07672. BD ).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
57P - Metastasis organotropism: Unveiling associated proteins using network biology
Presenter: Margarida Carrolo
Session: Poster session 09
59P - Correlation of tumor microenvironment signature in advanced stage non-small cell lung cancer with EGFR mutation who received EGFR-TKIs
Presenter: Chaiyapong Ngamchokwathana
Session: Poster session 09
60P - Establishment and characterization of a novel lung adenocarcinoma cell line HX-JCJ harboring MET ex14 skipping mutation
Presenter: Xuejin Ou
Session: Poster session 09
61P - Next generation sequencing and its clinical utility in advanced cancer: Single institute experience from low-middle income country
Presenter: Amit Badola
Session: Poster session 09
62P - Prebiotics modulate gut microbiota-mediated T cell immunity to enhance sintilimab inhibition of lung cancer
Presenter: QIN YAN
Session: Poster session 09
63P - Addition of human chorionic gonadotropin to the current standard mobilization approach with granulocyte-colony stimulating factor increases overall survival in a murine model of peripheral blood stem cell transplantation: Are we far enough for therapy?
Presenter: Andrei Cismaru
Session: Poster session 09
64P - Developing novel therapeutics for bladder cancer leveraging drosophila models
Presenter: Takuya Moriguchi
Session: Poster session 09
65P - Ionizing radiation induces vascular smooth muscle cell senescence through activating NF-κB-CTCF-p16 pathway
Presenter: xuefeng zheng
Session: Poster session 09
66P - Exploring the radiobiology and dosimetry of targeted alpha therapy as a tool to optimize its clinical application: A preclinical study
Presenter: Maria Filomena Botelho
Session: Poster session 09
67P - The effect of non-viral gene-immune therapy via OX40L or 4-1BBL on murine subcutaneous CT26 colon cancer model
Presenter: Olga Rakitina
Session: Poster session 09